Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells

References

• Kong FH, Ye QF, Miao XY, et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 2021;11(11):5464–5490. doi:10.7150/thno.54822
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Hourdequin KC, Schpero WL, McKenna DR, et al. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Ann Oncol. 2013;24(12):2952–2962. doi:10.1093/annonc/mdt294
   PubMed Web of Science ®Google Scholar
• Krukiewicz K, Zak JK. Biomaterial-based regional chemotherapy: local anticancer drug delivery to enhance chemotherapy and minimize its side-effects. Mater Sci Eng C. 2016;62:927–942. doi:10.1016/j.msec.2016.01.063
   PubMed Web of Science ®Google Scholar
• Miyahara T, Sueoka-Aragane N, Iwanaga K, et al. Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer. Med Oncol. 2017;34(12):195. doi:10.1007/s12032-017-1053-8
   PubMed Web of Science ®Google Scholar
• Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine. 2010;5(4):597–615. doi:10.2217/nnm.10.35
   PubMed Web of Science ®Google Scholar
• Khan MI, Hossain MI, Hossain MK, et al. Recent progress in nanostructured smart drug delivery systems for cancer therapy: a review. ACS Appl Bio Mater. 2022;5(3):971–1012. doi:10.1021/acsabm.2c00002
   PubMedGoogle Scholar
• Lu Y, Luo Q, Jia X, et al. Multidisciplinary strategies to enhance therapeutic effects of flavonoids from Epimedii Folium: integration of herbal medicine, enzyme engineering, and nanotechnology. J Pharm Anal. 2023;13(3):239–254. doi:10.1016/j.jpha.2022.12.001
   PubMed Web of Science ®Google Scholar
• Silva JO, Fernandes RS, Lopes SCA, et al. pH-Sensitive, long-circulating liposomes as an alternative tool to deliver doxorubicin into tumors: a feasibility animal study. Mol Imaging Biol. 2016;18(6):898–904. doi:10.1007/s11307-016-0964-7
   PubMed Web of Science ®Google Scholar
• Feng L, Gao M, Tao D, et al. Cisplatin-prodrug-constructed liposomes as a versatile theranostic nanoplatform for bimodal imaging guided combination cancer therapy. Adv Funct Mater. 2016;26(13):2207–2217. doi:10.1002/adfm.201504899
   Web of Science ®Google Scholar
• Wang Y, Zhang H, Hao J, et al. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug Deliv. 2016;23(4):1398–1403. doi:10.3109/10717544.2015.1055619
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang H, Cui H, et al. Combined and targeted drugs delivery system for colorectal cancer treatment: conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers. Drug Deliv. 2022;29(1):342–350. doi:10.1080/10717544.2022.2027573
   PubMed Web of Science ®Google Scholar
• Gupta L, Sharma AK, Gothwal A, et al. Dendrimer encapsulated and conjugated delivery of berberine: a novel approach mitigating toxicity and improving in vivo pharmacokinetics. Int J Pharm. 2017;528(1–2):88–99. doi:10.1016/j.ijpharm.2017.04.073
   PubMed Web of Science ®Google Scholar
• Wei T, Chen C, Liu J, et al. Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. Proc Natl Acad Sci USA. 2015;112(10):2978–2983. doi:10.1073/pnas.1418494112
   PubMed Web of Science ®Google Scholar
• Zhu M, Chen S, Hua L, et al. Self-targeted salinomycin-loaded DSPE-PEG-methotrexate nanomicelles for targeting both head and neck squamous cell carcinoma cancer cells and cancer stem cells. Nanomedicine. 2017;12(4):295–315. doi:10.2217/nnm-2016-0382
   PubMed Web of Science ®Google Scholar
• Yu L, Lin C, Zheng Z, et al. Self-assembly of pH-responsive biodegradable mixed micelles based on anionic and cationic polycarbonates for doxorubicin delivery. Colloids Surf B. 2016;145:392–400. doi:10.1016/j.colsurfb.2016.05.029
   PubMed Web of Science ®Google Scholar
• Hasannia M, Aliabadi A, Abnous K, et al. Synthesis of block copolymers used in polymersome fabrication: application in drug delivery. J Control Release. 2022;341:95–117. doi:10.1016/j.jconrel.2021.11.010
   PubMed Web of Science ®Google Scholar
• Li X, Hetjens L, Wolter N, et al. Charge-reversible and biodegradable chitosan-based microgels for lysozyme-triggered release of vancomycin. J Adv Res. 2023;43:87–96. doi:10.1016/j.jare.2022.02.014
   PubMed Web of Science ®Google Scholar
• Li X, Sun H, Li H, et al. Multi-responsive biodegradable cationic nanogels for highly efficient treatment of tumors. Adv Funct Mater. 2021;31(26):2100227. doi:10.1002/adfm.202100227
   Web of Science ®Google Scholar
• Yao X, Niu X, Ma K, et al. Graphene quantum dots-capped magnetic mesoporous silica nanoparticles as a multifunctional platform for controlled drug delivery, magnetic hyperthermia, and photothermal therapy. Small. 2017;13(2):1602225. doi:10.1002/smll.201602225
   Web of Science ®Google Scholar
• Wang H, Zhang M, Zhang L, et al. Near-infrared light and pH-responsive Au@carbon/calcium phosphate nanoparticles for imaging and chemo-photothermal cancer therapy of cancer cells. Dalt Trans. 2017;46(43):14746–14751. doi:10.1039/C7DT02274C
   PubMed Web of Science ®Google Scholar
• Chen J, Gong M, Fan Y, et al. Collective plasmon coupling in gold nanoparticle clusters for highly efficient photothermal therapy. ACS Nano. 2022;16(1):910–920. doi:10.1021/acsnano.1c08485
   PubMed Web of Science ®Google Scholar
• Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B. Gold nanoparticles in cancer treatment. Mol Pharm. 2019;16(1):1–23. doi:10.1021/acs.molpharmaceut.8b00810
   PubMed Web of Science ®Google Scholar
• Lee KX, Shameli K, Mohamad SE, et al. Bio-mediated synthesis and characterisation of silver nanocarrier, and its potent anticancer action. Nanomaterials. 2019;9(10):1423. doi:10.3390/nano9101423
   Web of Science ®Google Scholar
• Miranda RR, Sampaio I, Zucolotto V. Exploring silver nanoparticles for cancer therapy and diagnosis. Colloids Surf B. 2022;210:112254. doi:10.1016/j.colsurfb.2021.112254
   PubMed Web of Science ®Google Scholar
• Zhi D, Yang T, Yang J, et al. Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy. Acta Biomater. 2020;102:13–34. doi:10.1016/j.actbio.2019.11.027
   PubMed Web of Science ®Google Scholar
• Zhao Q, Lin Y, Han N, et al. Mesoporous carbon nanomaterials in drug delivery and biomedical application. Drug Deliv. 2017;24(2):94–107. doi:10.1080/10717544.2017.1399300
   PubMed Web of Science ®Google Scholar
• Mohajeri M, Behnam B, Sahebkar A. Biomedical applications of carbon nanomaterials: drug and gene delivery potentials. J Cell Physiol. 2018;234(1):298–319. doi:10.1002/jcp.26899
   PubMed Web of Science ®Google Scholar
• Watermann A, Brieger J. Mesoporous silica nanoparticles as drug delivery vehicles in cancer. Nanomaterials. 2017;7(7):189. doi:10.3390/nano7070189
   Web of Science ®Google Scholar
• Vallet-Regí M, Schüth F, Lozano D, et al. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem Soc Rev. 2022;51(13):5365–5451. doi:10.1039/d1cs00659b
   PubMed Web of Science ®Google Scholar
• Hua XW, Bao YW, Wu FG. Fluorescent carbon quantum dots with intrinsic nucleolus-targeting capability for nucleolus imaging and enhanced cytosolic and nuclear drug delivery. ACS Appl Mater Interfaces. 2018;10(13):10664–10677. doi:10.1021/acsami.7b19549
   PubMed Web of Science ®Google Scholar
• Xu X, Ho W, Zhang X, et al. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med. 2015;21(4):223–232. doi:10.1016/j.molmed.2015.01.001
   PubMed Web of Science ®Google Scholar
• Dancy JG, Wadajkar AS, Connolly NP, et al. Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer. Sci Adv. 2020;6(3):eaax3931. doi:10.1126/sciadv.aax3931
   PubMed Web of Science ®Google Scholar
• Wang Y, Qin B, Xia G, et al. FDA’s poly (lactic-co-glycolic acid) research program and regulatory outcomes. AAPS J. 2021;23(4):92. doi:10.1208/s12248-021-00611-y
   PubMed Web of Science ®Google Scholar
• Su Y, Zhang B, Sun R, et al. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Deliv. 2021;28(1):1397–1418. doi:10.1080/10717544.2021.1938756
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Galle PR. Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war. J Hepatol. 2008;49(5):871–873. doi:10.1016/j.jhep.2008.09.001
   PubMedGoogle Scholar
• Zhu YJ, Zheng B, Wang HY, et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38(5):614–622. doi:10.1038/aps.2017.5
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–11858. doi:10.1158/0008-5472.CAN-06-1377
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–1917. doi:10.1016/S0140-6736(03)14964-1
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi:10.1002/hep.24199
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–7109. doi:10.1158/0008-5472.CAN-04-1443
   PubMed Web of Science ®Google Scholar
• Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59(5):561–574. doi:10.1007/s00280-006-0393-4
   PubMed Web of Science ®Google Scholar
• Su GL, Altayar O, O’Shea R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162(3):920–934. doi:10.1053/j.gastro.2021.12.276
   PubMed Web of Science ®Google Scholar
• Doycheva I, Thuluvath PJ. Systemic therapy for advanced hepatocellular carcinoma: an update of a rapidly evolving field. J Clin Exp Hepatol. 2019;9(5):588–596. doi:10.1016/j.jceh.2019.07.012
   PubMed Web of Science ®Google Scholar
• Zhang Z, Niu B, Chen J, et al. The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer. Biomaterials. 2014;35(15):4565–4572. doi:10.1016/j.biomaterials.2014.02.024
   PubMed Web of Science ®Google Scholar
• Blanchet B, Billemont B, Cramard J, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal. 2009;49(4):1109–1114. doi:10.1016/j.jpba.2009.02.008
   PubMed Web of Science ®Google Scholar
• Rahiminezhad Z, Tamaddon AM, Dehshahri A, et al. PLGA-graphene quantum dot nanocomposites targeted against αvβ3 integrin receptor for sorafenib delivery in angiogenesis. Biomater Adv. 2022;137:212851. doi:10.1016/j.bioadv.2022.212851
   PubMedGoogle Scholar
• Feczkó T, Piiper A, Pleli T, et al. Theranostic sorafenib-loaded polymeric nanocarriers manufactured by enhanced gadolinium conjugation techniques. Pharmaceutics. 2019;11(10):489. doi:10.3390/pharmaceutics11100489
   PubMed Web of Science ®Google Scholar
• Babos G, Biró E, Meiczinger M, et al. Dual drug delivery of sorafenib and doxorubicin from PLGA and PEG-PLGA polymeric nanoparticles. Polymers. 2018;10(8):895. doi:10.3390/polym10080895
   PubMed Web of Science ®Google Scholar
• Khan MA, Raza A, Ovais M, et al. Current state and prospects of nano-delivery systems for sorafenib. Int J Polym Mater Polym Biomater. 2018;67(18):1105–1115. doi:10.1080/00914037.2018.1429434
   Web of Science ®Google Scholar
• Liu J, Boonkaew B, Arora J, et al. Comparison of sorafenib-loaded poly (Lactic/Glycolic) acid and dppc liposome nanoparticles in the in vitro treatment of renal cell carcinoma. J Pharm Sci. 2015;104(3):1187–1196. doi:10.1002/jps.24318
   PubMed Web of Science ®Google Scholar
• Liu Y, Feng L, Liu T, et al. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale. 2014;6(6):3231–3242. doi:10.1039/c3nr05647c
   PubMed Web of Science ®Google Scholar
• Kim DH, Kim MD, Choi CW, et al. Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(DL-lactide-co-glycolide) block copolymer. Nanoscale Res Lett. 2012;7:91. doi:10.1186/1556-276X-7-91
   PubMed Web of Science ®Google Scholar
• Malarvizhi GL, Retnakumari AP, Nair S, et al. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. Biol Med. 2014;10(8):1649–1659. doi:10.1016/j.nano.2014.05.011
   Google Scholar
• Zhang J, Hu J, Chan HF, et al. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. Biol Med. 2016;12(5):1303–1311. doi:10.1016/j.nano.2016.01.017
   Google Scholar
• Caputo TM, Aliberti A, Cusano AM, et al. Stimuli‐responsive hybrid microgels for controlled drug delivery: sorafenib as a model drug. J Appl Polym Sci. 2021;138(14):50147. doi:10.1002/app.50147
   Web of Science ®Google Scholar
• Caputo TM, Cusano AM, Ruvo M, et al. Human serum albumin nanoparticles as a carrier for on-demand sorafenib delivery. Curr Pharm Biotechnol. 2021;23(9):1214–1225.
   Web of Science ®Google Scholar
• Giannouli M, Karagkiozaki V, Pappa F, et al. Fabrication of quercetin-loaded PLGA nanoparticles via electrohydrodynamic atomization for cardiovascular disease. Mater Today. 2018;5(8):15998–16005.
   Google Scholar
• Maity S, Chakraborti AS. Formulation, physico-chemical characterization and antidiabetic potential of naringenin-loaded poly D, L lactide-co-glycolide (N-PLGA) nanoparticles. Eur Polym J. 2020;134:109818. doi:10.1016/j.eurpolymj.2020.109818
   Web of Science ®Google Scholar
• Wei JC, Meng F, Qu K, et al. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. Acta Pharmacol Sin. 2015;36(2):241–251. doi:10.1038/aps.2014.122
   PubMed Web of Science ®Google Scholar
• Carotenuto B, Ricciardi A, Micco A, et al. Smart optical catheters for epidurals. Sensors. 2018;18(7):2101. doi:10.3390/s18072101
   PubMed Web of Science ®Google Scholar
• Monat C, Domachuk P, Eggleton BJ. Integrated optofluidics: a new river of light. Nat Photonics. 2007;1(2):106–114. doi:10.1038/nphoton.2006.96
   Web of Science ®Google Scholar
• Fan X, White IM. Optofluidic microsystems for chemical and biological analysis. Nat Photonics. 2011;5(10):591–597. doi:10.1038/nphoton.2011.206
   PubMed Web of Science ®Google Scholar
• Sui K, Meneghetti M, Kaur J, et al. Microstructured soft fiber-based neural device for drug delivery and optical neuromodulation. Biophotonics Congr Biomed Opt. 2022;2022:BW4C.3.
   Google Scholar
• Nazari M, Rubio-Martinez M, Tobias G, et al. Metal-organic-framework-coated optical fibers as light-triggered drug delivery vehicles. Adv Funct Mater. 2016;26(19):3244–3249. doi:10.1002/adfm.201505260
   Web of Science ®Google Scholar
• Wang X, Dong X, Zhou Y, et al. Optical fiber anemometer using silver-coated fiber Bragg grating and bitaper. Sens Actuator a Phys. 2014;214:230–233. doi:10.1016/j.sna.2014.04.013
   Web of Science ®Google Scholar
• Yang J, Chen X, Dong X. Hot-wire anemometer based on frosted fiber Bragg grating coated with silver film. Mater Sci Eng. 2020;711:012112.
   Google Scholar
• Caldas P, Jorge PAS, Rego G, et al. Fiber optic hot-wire flowmeter based on a metallic coated hybrid long period grating/fiber Bragg grating structure. Appl Opt. 2011;50(17):2738–2743. doi:10.1364/AO.50.002738
   PubMed Web of Science ®Google Scholar
• Gao R, Lu D. Temperature compensated fiber optic anemometer based on graphene-coated elliptical core micro-fiber Bragg grating. Opt Express. 2019;27(23):34011–34021. doi:10.1364/OE.27.034011
   PubMed Web of Science ®Google Scholar
• Silva GE, Caldas P, Santos JC, et al. All-fiber sensor based on a metallic coated hybrid LPG-FBG structure for thermal characterization of materials. In: 23rd International Conference on Optical Fibre Sensors. SPIE; 2014:241–244.
   Google Scholar
• Liu Z, Wang F, Zhang Y, et al. Low-power-consumption fiber-optic anemometer based on long-period grating with SWCNT coating. IEEE Sens J. 2019;19(7):2592–2597. doi:10.1109/JSEN.2019.2891044
   Web of Science ®Google Scholar
• Zhang Y, Wang F, Liu Z, et al. Fiber-optic anemometer based on single-walled carbon nanotube coated tilted fiber Bragg grating. Opt Express. 2017;25(20):24521–24530. doi:10.1364/OE.25.024521
   PubMed Web of Science ®Google Scholar
• Liu Y, Liang B, Zhang X, et al. Plasmonic fiber-optic photothermal anemometers with carbon nanotube coatings. J Light Technol. 2019;37(13):3373–3380. doi:10.1109/JLT.2019.2916572
   Web of Science ®Google Scholar
• Wang F, Duan Y, Lu M, et al. Linear-response and simple hot-wire fiber-optic anemometer using high-order cladding mode. Opt Express. 2020;28(18):27028–27036. doi:10.1364/OE.399774
   PubMed Web of Science ®Google Scholar
• Alvi M, Yaqoob A, Rehman K, et al. PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives. AAPS Open. 2022;8(1):1–17. doi:10.1186/s41120-022-00060-7
   PubMedGoogle Scholar
• Hernández-Giottonini KY, Rodríguez-Córdova RJ, Gutiérrez-Valenzuela CA, et al. PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters. RSC Adv. 2020;10(8):4218–4231. doi:10.1039/C9RA10857B
   PubMed Web of Science ®Google Scholar
• Martins C, Sousa F, Araújo F, et al. Poly(lactic-co-glycolic) acid: functionalizing PLGA and PLGA derivatives for drug delivery and tissue regeneration applications. Adv Healthc Mater. 2018;7(1). doi:10.1002/adhm.201701035
   Web of Science ®Google Scholar
• Toy R, Peiris PM, Ghaghada KB, et al. Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine. 2014;9(1):121–134. doi:10.2217/nnm.13.191
   PubMed Web of Science ®Google Scholar
• Zhou F, Teng F, Deng P, et al. Recent progress of nano-drug delivery system for liver cancer treatment. Anticancer Agents Med Chem. 2017;17(14):1884–1897.
   Web of Science ®Google Scholar
• Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263(5153):1600–1603. doi:10.1126/science.8128245
   PubMed Web of Science ®Google Scholar
• Jeong Y, Kim DH, Chung CW, et al. Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer. Int J Nanomedicine. 2011;6:1415–1427. doi:10.2147/IJN.S19491
   PubMed Web of Science ®Google Scholar